SCHEMBL6569227

SCHEMBL6569227

O=C(NN=Cc1ccc(O)cc1O)c1cccc(Cl)c1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 2/20 0.77
SIRT1 Q96EB6 1/20 0.64
NPC1 O15118 5/20 0.63
RAB9A P51151 5/20 0.63
MEN1 O00255 4/20 0.63
KMT2A Q03164 4/20 0.63
NTRK1 P04629 1/20 0.61
POLB P06746 2/20 0.59
ALPL P05186 1/20 0.59
ALPI P09923 1/20 0.59
ALPG P10696 1/20 0.59
EIF4H Q15056 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
GUSB P08236 1/20 0.58
MAPT P10636 3/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
CYP1A2 P05177 1/20 0.58
CYP3A4 P08684 1/20 0.58
CYP2D6 P10635 1/20 0.58
CYP2C9 P11712 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6569224 1.00 KDM1A (0.77) KDM1ASIRT1NPC1RAB9AMEN1
SCHEMBL684219 0.92 KDM1A (0.81) KDM1ANPC1RAB9AMEN1KMT2A
SCHEMBL6570169 0.90 KDM1A (0.77) KDM1ANPC1RAB9AMEN1KMT2A
SCHEMBL6570173 0.90 KDM1A (0.77) KDM1ANPC1RAB9AMEN1KMT2A
SCHEMBL28515473 0.89 SIRT1 (0.70) KDM1ASIRT1NPC1RAB9AMEN1
SCHEMBL12746249 0.87 KDM1A (0.69) KDM1ANPC1RAB9AMEN1KMT2A
SCHEMBL684939 0.87 KDM1A (1.00) KDM1ANPC1RAB9AMEN1KMT2A
SCHEMBL6751418 0.85 SIRT1 (0.72) KDM1ASIRT1NPC1RAB9AMEN1
SCHEMBL10049701 0.85 SIRT1 (0.72) KDM1ASIRT1NPC1RAB9AMEN1
SCHEMBL6751415 0.85 SIRT1 (0.72) KDM1ASIRT1NPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110963-A1 Novel hydrazones ARPIDA AG (CH) 2004-06-10 US disclosed
EP-1404644-A2 NOVEL HYDRAZONES Arpida AG, (CH) 2004-04-07 EP disclosed
WO-2002070464-A2 HYDRAZONES AND THEIR THERAPEUTIC USE ARPIDA AG (CH) 2002-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110963-A1 Novel hydrazones H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HK1, MPO KDM1A 2684/4885SIRT1 164/4885NPC1 785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.